Tilvestamab-MMAE, an antibody-drug conjugate (ADC), comprises an AXL-targeting antibody linked to Monomethyl auristatin E (MMAE). It is utilized in research focused on acute myeloid leukemia and solid tumors.
Target:
TAM Receptor
* VAT and and shipping costs not included. Errors and price changes excepted